Crown Holdings is a global manufacturer of packaging products for consumer goods. Crown makes variety of steel and aluminum cans for food, beverage, household, and other consumer products and metal vacuum closures, steel crowns and caps. The company has 5 operating segments. Americas Beverage - The division manufactures aluminum beverage cans and ends, steel crowns, glass bottles and aluminum closures. European Beverage - The segment manufactures steel and aluminum beverage cans and ends. European Food - The segment manufactures steel and aluminum food cans, ends and metal vacuum closures. Crown Holdings completed the sale of its European Tinplate business to KPS Capital Partners. The business comprises the European Food segment and its European Aerosol and Promotional Packaging reporting unit. The business consists of manufacturing plants across Europe, Middle East and Africa. The Transit Packaging segment includes the company's global industrial and protective solutions and equipment and tools businesses....
+See MoreSharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 14 March 2026
2019-08-03 09:28:00 Saturday ET

U.S. inflation has become sustainably less than the 2% policy target in recent years. As Harvard macro economist Robert Barro indicates, U.S. inflation has
2018-03-25 08:39:00 Sunday ET

President Trump imposes punitive tariffs on $60 billion Chinese imports in a brand-new trade war as China hits back with retaliatory tariffs on $3 billion U
2018-05-21 07:39:00 Monday ET

Dodd-Frank rollback raises the asset threshold for systemically important financial institutions (SIFIs) from $50 billion to $250 billion. This legislative
2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be
2023-07-28 11:28:00 Friday ET

Lucian Bebchuk and Jesse Fried critique that executive pay often cannot help explain the stock return and operational performance of most U.S. public corpor
2019-08-22 11:35:00 Thursday ET

Fundamental factors often reflect macroeconomic innovations and so help inform better stock investment decisions. Nobel Laureate Eugene Fama and his long-ti